Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of an oral pentavalent reassortant rotavirus live vaccine (Vero cell) in Chinese infants
CTR20241121Phase 2Active
- Sponsor
- 深圳康泰生物制品股份有限公司；北京民海生物科技有限公司/ 深圳康泰生物制品股份有限公司
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rotavirus vaccine, live, oral, pentavalent in rotaviral diarrhea, sponsored by 深圳康泰生物制品股份有限公司；北京民海生物科技有限公司/ 深圳康泰生物制品股份有限公司. Started Mar 2024; status: active.
02
Drugs
rotavirus vaccine, live, oral, pentavalent
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on CTR20241121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241121.